Preclinical and clinical studies have revealed that SCFAs can increase the secretion of intestinal hormones, such as GLP-1, GLP-2, and PYY (reducing appetite), and decrease the level of systemic inflammatory cytokines by disrupting lipid breakdown, and therefore increase energy consumption and lipid oxidation to alleviate obesity [52]. The gene discussed is PYY; the disease is obesity disorder.